tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2020-10-4-21-29tumors-744Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISНиволумаб: 5 лет со дня международной регистрации иммунотерапии метастатического рака почкиNivolumab: 5 years from the day of international registration of immunotherapy of metastatic kidney cancerТимофеевИ. В.TsimafeyeuI. V.

Илья В. Тимофеев, онколог, директор Института онкологии Хадасса 

Москва

Ilya V. Tsimafeyeu, Oncologist, Director of the Institute of Oncology 

Moscow

Институт онкологии ХадассаРоссияInstitute of Oncology Hadassah MedicalRussian Federation2020020220211042129Copyright © Тимофеев И.В., 20212021Тимофеев И.В.Tsimafeyeu I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/744

Пять лет назад, 23 ноября 2015 года, Управление по контролю над качеством пищевых продуктов и лекарственных препаратов США (FDA) одобрило ниволумаб для лечения метастатического почечно-клеточного рака, открыв, тем самым, новую эру иммунотерапии этой опухоли. Целью настоящего обзора является систематизация накопленных результатов исследований ниволумаба в монотерапии и в комбинациях.

Five years ago, on November 23, 2015, the US Food and Drug Administration (FDA) approved nivolumab for the treatment of metastatic renal cell carcinoma, thus ushering in a new era of immunotherapy for this tumor. The purpose of this review is to systematize the accumulated results of studies of nivolumab in monotherapy and in combinations.

ниволумабпочечно-клеточный ракметастазыnivolumabrenal cell carcinomametastasesReferencesСаяпина М.С., Савелов Н.А., Любимова H.В., с соавт. Анализ результатов лечения больных метастатическим раком почки, получавших анти-PD-1‑терапию в рамках программы расширенного доступа: клиническая эффективность и потенциальные биомаркеры ниволумаба. Злокачественные опухоли. 2018;8(3):31-38.Саяпина М.С., Савелов Н.А., Любимова H.В., с соавт. Анализ результатов лечения больных метастатическим раком почки, получавших анти-PD-1‑терапию в рамках программы расширенного доступа: клиническая эффективность и потенциальные биомаркеры ниволумаба. Злокачественные опухоли. 2018;8(3):31-38.Porta C, Bonomi L, Lillaz B, et al. Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. Anticancer Res. 2007; 27(1A): 165-173.Porta C, Bonomi L, Lillaz B, et al. Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. Anticancer Res. 2007; 27(1A): 165-173.Tsimafeyeu I, Volkova M, Olshanskaia A, et al. Expression of Receptor Tyrosine Kinases on Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes in Patients with Renal Cell Carcinoma and Healthy Donors. Oncology. 2020;98(4):252-258. doi: 10.1159/000505373. Epub 2020 Feb 13. PMID: 32053815.Tsimafeyeu I, Volkova M, Olshanskaia A, et al. Expression of Receptor Tyrosine Kinases on Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes in Patients with Renal Cell Carcinoma and Healthy Donors. Oncology. 2020;98(4):252-258. doi: 10.1159/000505373. Epub 2020 Feb 13. PMID: 32053815.Ueda K, Suekane S, Kurose H, et al. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma. Urol Oncol. 2018; 36(11): 499.e9-499.e16.Ueda K, Suekane S, Kurose H, et al. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma. Urol Oncol. 2018; 36(11): 499.e9-499.e16.Zhang X, Yin X, Zhang H, et al. Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. BMC Cancer. 2019; 19, 360.Zhang X, Yin X, Zhang H, et al. Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. BMC Cancer. 2019; 19, 360.Kahlmeyer A, Stöhr CG, Hartmann A, et al. Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma. J Clin Med. 2019; 8(5): 743.Kahlmeyer A, Stöhr CG, Hartmann A, et al. Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma. J Clin Med. 2019; 8(5): 743.Giraldo NA, Becht E, Vano Y, et al. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2017; 23(15): 4416-4428.Giraldo NA, Becht E, Vano Y, et al. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2017; 23(15): 4416-4428.Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009; 10(1): 29-37.Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009; 10(1): 29-37.Meylan M, Beuselinck B, Dalban C, et al. Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to Nivolumab (N). ESMO Virtual Congress 2020. Abstract 700O.Meylan M, Beuselinck B, Dalban C, et al. Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to Nivolumab (N). ESMO Virtual Congress 2020. Abstract 700O.Демидов Л.В., Харкевич Г.Ю., Тимофеев И.В. Успехи и неудачи применения цитокинов в лекарственной терапии некоторых солидных опухолей. Практическая онкология, 4 (3-2003), 140.Демидов Л.В., Харкевич Г.Ю., Тимофеев И.В. Успехи и неудачи применения цитокинов в лекарственной терапии некоторых солидных опухолей. Практическая онкология, 4 (3-2003), 140.Носов Д.А., Воробьев Н.А., Гладков О.А., с соавт. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли, 2015, №4, спецвыпуск, С.281-285.Носов Д.А., Воробьев Н.А., Гладков О.А., с соавт. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли, 2015, №4, спецвыпуск, С.281-285.Tsimafeyeu I, Demidov L, Kharkevich G, et al. (2010) Granulocyte-Macrophage Colony-Stimulating Factor, Interferon Alpha andInterleukin-2 as Adjuvant Treatment for High-Risk Renal Cell Carcinoma. J Cancer Sci Ther 2: 157-159. doi:10.4172/1948-5956.1000042Tsimafeyeu I, Demidov L, Kharkevich G, et al. (2010) Granulocyte-Macrophage Colony-Stimulating Factor, Interferon Alpha andInterleukin-2 as Adjuvant Treatment for High-Risk Renal Cell Carcinoma. J Cancer Sci Ther 2: 157-159. doi:10.4172/1948-5956.1000042Xu JX, Maher VE, Zhang L, Tang S, Sridhara R, Ibrahim A, Kim G, Pazdur R. FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis. Oncologist. 2017 Mar;22(3):311-317. doi: 10.1634/theoncologist.2016-0476.Xu JX, Maher VE, Zhang L, Tang S, Sridhara R, Ibrahim A, Kim G, Pazdur R. FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis. Oncologist. 2017 Mar;22(3):311-317. doi: 10.1634/theoncologist.2016-0476.Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19): 1803-1813.Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19): 1803-1813.Motzer R, Tykodi S, Escudier B, et al. Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2020; 38 (suppl 6; abstr 617).Motzer R, Tykodi S, Escudier B, et al. Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2020; 38 (suppl 6; abstr 617).Tsimafeyeu I, Zolotareva T, Varlamov S, et al. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry. Clin Genitourin Cancer. 2017 Dec; 15(6): e1069-e1072.Tsimafeyeu I, Zolotareva T, Varlamov S, et al. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry. Clin Genitourin Cancer. 2017 Dec; 15(6): e1069-e1072.SEER database 2020. https://seer.cancer.gov/statfacts/html/kidrp.htmlSEER database 2020. https://seer.cancer.gov/statfacts/html/kidrp.htmlMotzer RJ, Rini BI, McDermott DF, et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2015 May 1;33(13):1430-7.Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2015 May 1;33(13):1430-7.Albiges L., Negrier S., Dalban C., et al. Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study. J Clin Oncol 37, 2019 (no. 7_suppl (March 01, 2019) 542542.). doi: 10.1200/JCO.2019.37.7_suppl.542.Albiges L., Negrier S., Dalban C., et al. Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study. J Clin Oncol 37, 2019 (no. 7_suppl (March 01, 2019) 542542.). doi: 10.1200/JCO.2019.37.7_suppl.542.Albiges L., Negrier S., Dalban C., et al. Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Results from the NIVOREN GETUG-AFU 26 study. J Clin Oncol 36, 2018 (suppl 6S; abstr 577).Albiges L., Negrier S., Dalban C., et al. Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Results from the NIVOREN GETUG-AFU 26 study. J Clin Oncol 36, 2018 (suppl 6S; abstr 577).Flippot R, Dalban C, Laguerre B, et al. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218.Flippot R, Dalban C, Laguerre B, et al. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218.Tsimafeyeu I, Gafanov R, Protsenko S, et al. Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection. Cancer Immunol Immunother. 2020 Jun;69(6):983-988. doi: 10.1007/s00262-020-02521-y.Tsimafeyeu I, Gafanov R, Protsenko S, et al. Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection. Cancer Immunol Immunother. 2020 Jun;69(6):983-988. doi: 10.1007/s00262-020-02521-y.Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5; 378(14): 1277-1290.Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5; 378(14): 1277-1290.Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020;5:e001079. doi: 10.1136/esmoopen-2020-001079.Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020;5:e001079. doi: 10.1136/esmoopen-2020-001079.Тимофеев И.В., Варламов И.С., Петкау В.В., с соавт. Продолжительность жизни больных метастатическим почечно-клеточным раком в Российской Федерации: результаты многоцентрового регистрового исследования RENSUR3. Злокачественные опухоли. 2019;9(2):45-52. https://doi.org/10.18027/2224-5057-2019-9-2-45-52Тимофеев И.В., Варламов И.С., Петкау В.В., с соавт. Продолжительность жизни больных метастатическим почечно-клеточным раком в Российской Федерации: результаты многоцентрового регистрового исследования RENSUR3. Злокачественные опухоли. 2019;9(2):45-52. https://doi.org/10.18027/2224-5057-2019-9-2-45-52Tannir NM, McDermott DF, Escudier B, et al. Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2020; 38 (suppl 6; abstr 609).Tannir NM, McDermott DF, Escudier B, et al. Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2020; 38 (suppl 6; abstr 609).Носов Д. А., Алексеев Б. Я., Волкова М. И., Гладков О. А., Попов А. М., Харкевич Г. Ю. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020 (том 10).31Носов Д. А., Алексеев Б. Я., Волкова М. И., Гладков О. А., Попов А. М., Харкевич Г. Ю. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020 (том 10).31NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, version 2.2020.NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, version 2.2020.McKay R, Xie W, McGregor B, et al. Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE). J Clin Oncol 38: 2020 (suppl; abstr 5005).McKay R, Xie W, McGregor B, et al. Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE). J Clin Oncol 38: 2020 (suppl; abstr 5005).Atkins M, Jegede O, Haas N, et al. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). J Clin Oncol 38: 2020 (suppl; abstr 5006).Atkins M, Jegede O, Haas N, et al. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). J Clin Oncol 38: 2020 (suppl; abstr 5006).Choueiri TK, Kluger HM, George S, et al. FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC). J Clin Oncol 38: 2020 (suppl; abstr 5007).Choueiri TK, Kluger HM, George S, et al. FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC). J Clin Oncol 38: 2020 (suppl; abstr 5007).Vano Y., Elaidi R.T., Bennamoun M, et al. Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial. Annals of Oncology, Volume 31, Supplement 4, 2020, Page S1157, Abstract LBA25.Vano Y., Elaidi R.T., Bennamoun M, et al. Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial. Annals of Oncology, Volume 31, Supplement 4, 2020, Page S1157, Abstract LBA25.Dengina N, Tsimafeyeu I, Mitin T. Current Role of Radiotherapy for Renal-Cell Carcinoma: Review. Clin Genitourin Cancer. 2017 Apr;15(2):183-187. doi: 10.1016/j.clgc.2016.09.004. Epub 2016 Sep 19.Dengina N, Tsimafeyeu I, Mitin T. Current Role of Radiotherapy for Renal-Cell Carcinoma: Review. Clin Genitourin Cancer. 2017 Apr;15(2):183-187. doi: 10.1016/j.clgc.2016.09.004. Epub 2016 Sep 19.Dengina N, Mitin T, Gamayunov S, et al. Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study. ESMO Open. 2019 Oct 13;4(5):e000535. doi: 10.1136/esmoopen-2019-000535.Dengina N, Mitin T, Gamayunov S, et al. Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study. ESMO Open. 2019 Oct 13;4(5):e000535. doi: 10.1136/esmoopen-2019-000535.Hammers H, Vonmerveldt D, Ahn C, et al. Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC). Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020) 614-614.Hammers H, Vonmerveldt D, Ahn C, et al. Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC). Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020) 614-614.Choueiri T, Powles M, Burotto M, et al. 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325Choueiri T, Powles M, Burotto M, et al. 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. 2020 Sep 1.Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. 2020 Sep 1.

The authors declare that there are no conflicts of interest present.